Solvay and Aquatiq have concluded a joint-venture agreement regarding Aqua Pharma company, reinforcing their long-term collaboration to serve aquaculture customers. With this alliance, Solvay and Aqua Pharma aim to become a key aquaculture player by offering a wide range of sustainable and efficient solutions for sea lice control and Amoebic Gill Disease (AGD) to the salmon industry. Solvay and Aqua Pharma will put a strong focus on research & development, new products and new treatment methodology, and will further develop treatments for other fish species.
“This JV agreement consolidates Solvay’s position in the aquaculture market” says Georges Crauser, Solvay Peroxides Global Business Unit President”. “Together, we believe that our combined expertise will bring value to the growing aquaculture industry in facing both challenges of fish health and environment protection with sustainable solutions.”
Solvay will bring its deep expertise in hydrogen peroxide technology, while Aqua Pharma offers a state of the art dosing equipment for Solvay’s product Paramove® to safeguard animal welfare and the environment with maximum efficacy.
Aqua Pharma has the largest hydrolicer treatment unit which is a complementary sustainable solution offered to the customers to fight sea lice in Norway. “This partnership with a company like Solvay, established in more than 60 countries, will allow us to accelerate our development to better serve customer needs around the globe,” says Elvin Bugge, Aqua Pharma CEO. Aqua Pharma is investing in new treatment solutions and will provide to the market a new technology for PARAMOVE® treatment as from October 2019.
The main benefits and differences of PARAMOVE® compared to other medical treatments, is that there is zero toxicity and no persistence in the environment. Hydrogen peroxide is recognized as one of the cleanest solution treatment for sea lice as it decomposes into water and oxygen.